cafepharmaNov 21, 2023
Merck drops up to $610M on neuro disease-focused Caraway Therapeutics -- AstraZeneca’s Imfinzi Phase III trial raises trial design questions --Teva granted pretrial appeal in high-stakes Copaxone kickbacks case-- See more on our front page news http://bit.ly/w28kSd #merck #mergersandacquisitions #astrazeneca #imfinzi #clinicaltrials #tevapharm #copaxone #kickbacks #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

Cafepharma
cafepharmaOct 4, 2023
Drugmakers face uphill battle in Medicare negotiation suits -- Sanofi pays Teva $500M to join Merck, Roivant in red-hot bowel disease race -- Moderna combo COVID-19/flu vaccine succeeds in early-stage trial -- See more on our front page news http://bit.ly/w28kSd #medicare #inflationreductionact #sanofi #tevapharm #ibd #vaccines #moderna #covid19 #flu #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

Cafepharma